Depo-Provera Brain Tumor Lawsuit 2026: Who Qualifies, What Cases Are Worth, and How to File

If you were on the Depo-Provera shot for years and later got a meningioma diagnosis, the practical question is not “is there a lawsuit” — there is — but “do I qualify, what do I need, and how long do I have to act.” This is a claimant’s guide, not a news recap. It walks through eligibility, the records that make or break a case, how mass-tort value actually gets estimated, the filing process, fees, and the deadline mistakes that quietly kill strong claims.

Depo-Provera is Pfizer’s injectable contraceptive, medroxyprogesterone acetate (MPA), given once every three months. The convenience made it one of the most widely prescribed contraceptives for decades. The turning point was a 2024 case-control study published in the BMJ by a French research team: women using the drug for a year or more showed roughly a 5.55x higher risk of intracranial meningioma. That number spread fast and triggered a wave of filings. Worth remembering, though — the same study noted the absolute risk stays low. Litigation here is about whether the company adequately warned, not the raw size of the risk.

Do I actually qualify? Three gates

Eligibility comes down to clearing three gates.

Duration of use. The scientific basis plaintiffs rely on centers on a year or more of exposure, so most firms want to see roughly four doses (about twelve months) or longer. One or two shots is a much weaker causation story.

The diagnosis. The target injury is an intracranial meningioma. Spinal meningiomas and other brain tumors like glioblastoma sit outside this litigation’s science, so you need pathology or imaging that names the diagnosis precisely.

Where you were prescribed. U.S. prescribing and administration is the premise for a U.S. claim. Someone who used the drug in the States but now lives abroad may still be able to participate.

Gate	Threshold	Proof
Duration	Roughly 1 year (4+ doses)	Pharmacy records, insurance claims, clinic notes
Diagnosis	Confirmed intracranial meningioma	MRI or CT imaging, pathology, neurosurgery records
Jurisdiction	U.S. prescribing and use	U.S. clinic and pharmacy records

Clearing all three gets you through the door. It does not decide value — that is a separate layer built on how badly you were hurt.

Where MDL 3140 stands

Depo-Provera claims are consolidated in a multidistrict litigation, MDL 3140 — formally In re: Depo-Provera Products Liability Litigation — before Judge M. Casey Rodgers in the Northern District of Florida. Here is the point people get wrong most often: an MDL is not a class action.

In a class action, many people are bound into one representative case, and a judgment or settlement applies to everyone the same way. In an MDL, each plaintiff keeps their own lawsuit. Only the shared pretrial work — discovery, expert-witness challenges, common legal questions — is handled together, and compensation is sized to each plaintiff’s injury. That distinction matters for you personally: it means your own records, not a class average, decide what you receive.

The milestone that steers everything is the bellwether trial. A handful of representative cases go first; the jury reactions and damage figures they produce become the reference point for global settlement talks. That is exactly how consolidated product cases like the OneWheel Future Motion injury lawsuit MDL 3087 move from filing to resolution. On top of that timeline, the FDA added a meningioma warning to the Depo-Provera label in December 2025 — a step many read as weakening Pfizer’s federal-preemption defense.

How settlement value gets estimated

This is the most asked question and the one that demands the most caution. No amounts are locked in. Anyone quoting a specific payout before the first bellwether verdicts is guessing. What you can understand in advance is the logic — which facts push a case up or down.

Mass-tort compensation is usually organized into tiers by injury severity. The table below is not a price list; it shows which facts raise the tier.

Injury tier	Typical situation	Effect on value
Lower	Watchful waiting, no surgery	Lower band
Moderate	Radiation or partial resection	Rises with treatment and deficits
Higher	Craniotomy, permanent neurological damage	Adds future care and lost earnings
Highest	Severe disability or death	Wrongful-death and lost-lifetime-income top band

Common modifiers cut across all tiers. Longer use strengthens causation. A younger age at diagnosis increases future lost earnings. Clear surgical and pathology records shrink the room for a causation fight. On the other side, alternative causes — smoking, family history, other hormone therapies — are exactly what the defense probes. If you want to see why brain-related awards vary so much, the permanence-of-deficit logic in the traffic accident settlement calculation guide maps directly onto how these injuries are valued.

From intake to distribution: the process

Here is the sequence, and what to prepare at each step.

1. Free consultation and screening — duration, diagnosis, and jurisdiction are checked, usually by phone or online.
2. Record retrieval — pharmacy, insurer, and hospital records are requested, often by the firm under a signed authorization.
3. Retainer and fee agreement — the contingency rate and cost handling are put in writing.
4. Filing and MDL transfer — an individual complaint is filed and folded into MDL 3140.
5. Discovery and Plaintiff Fact Sheet — your use history, diagnosis, and medical background go in on a standardized form; omissions can jeopardize the case.
6. Bellwether trials and negotiation — representative results drive global talks.
7. Settlement and distribution — tier-based amounts are set, then fees and costs are deducted.

This can take months to years. The long wait tempts some plaintiffs into selling assets or taking high-interest lawsuit loans to bridge living expenses. Before doing either, run the math — the same discount-rate trap that makes people surrender future value cheaply is laid out in the viatical life settlement guide.

Choosing a lawyer and reading the fee

These cases favor firms with capital and real product-liability experience, because discovery front-loads heavy costs: expert causation testimony, records analysis, medical review. Check for:

• Contingency rate — usually 33 to 40 percent of recovery. Ask whether an MDL common-benefit assessment is added on top.
• Cost handling — confirm in writing whether expert and retrieval costs are deducted from your recovery, and that you owe nothing if there is no recovery.
• Track record — genuine mass-tort or medical-device experience, not a “referral mill” that signs volume and hands cases off.
• Communication — whether you actually reach the handling attorney and get regular updates.

The same intake and contingency mechanics that govern a surgical stapler malfunction lawsuit apply here — and firms that look identical on fee percentage often diverge sharply on cost treatment and responsiveness.

Deadlines and mistakes that kill strong cases

Plenty of qualifying claims collapse for avoidable reasons.

Missing the statute of limitations. Product-liability deadlines run roughly two to six years, but the discovery rule is decisive: the clock often starts when you knew or should have known of the link between the drug and your tumor. The 2024 study and its coverage may have advanced that awareness date for many people. If you already have a diagnosis, letting time slide is the single biggest risk.

Losing your records. Old pharmacy files and early MRIs take time to pull and scatter across provider changes and insurance switches. Request them early.

Being vague about the diagnosis. “Brain tumor” is not enough; the file needs to confirm an intracranial meningioma.

Trusting inflated advertising. “Guaranteed payout” language is a warning sign, not a credential — a caution that applies across every consolidated pharmaceutical case, including complex science-heavy ones like the toxic baby food heavy metals lawsuit MDL 3101.

Common mistake	Result	Fix
Deadline passes	Case dismissed	Consult and check the clock at diagnosis
Records not secured	Causation hard to prove	Request pharmacy and hospital files early
Wrong diagnosis assumed	Ineligible	Confirm meningioma via pathology and imaging
Inflated ads trusted	Poor firm choice	Verify track record and written terms

What separates a strong file from a weak one

Two people with the same eligibility can end up in very different negotiating positions depending on how dense their file is. Prioritize pulling these together early:

• A continuous record of use — pharmacy dispensing history, insurance claims, and clinic administration notes that stitch into an unbroken timeline make the duration argument hard to attack.
• Diagnostic confirmation — the earliest imaging (MRI or CT) and the pathology that pins the diagnosis specifically to an intracranial meningioma.
• Treatment course — craniotomy or radiation records, plus post-treatment assessments of any vision, hearing, cognitive, or seizure deficits, which is what lifts your injury tier.
• Income and work records — earnings before and after diagnosis, and any leave or job loss, which anchor a lost-wages calculation.

The reverse is just as true: scattered records, a vague diagnosis, or an incomplete medical history start you in a lower tier even when you clearly qualify. Preparation is not a formality here — it is leverage.

The causation fight: what the defense will argue

Understanding the other side’s playbook tells you exactly which parts of your file to shore up. Pfizer’s defense will run along a few predictable lines.

The first was federal preemption — the argument that FDA labeling rules preempt state failure-to-warn claims, so the company cannot be sued for not adding a warning the FDA had not required. The December 2025 label change undercuts that line, because the warning the plaintiffs said was missing now exists. It does not erase the defense entirely, but it changes the terrain.

The second is alternative causation. Meningiomas have known associations beyond hormones — prior radiation exposure, certain genetic conditions, and simply age and sex, since these tumors are more common in women and rise with age. The defense will comb your history for any of these and argue the tumor would have appeared regardless of the drug. A clean record that documents the timeline — years of use, then a diagnosis, with no obvious competing cause — is the strongest answer.

The third is the absolute-risk argument. Because the BMJ study emphasized that the elevated risk still translates to a small number of cases per ten thousand users, the defense will press that the epidemiology shows association, not proof that the drug caused your tumor. Plaintiffs counter with dose-response logic: risk rising with longer use is the pattern you expect from a real causal effect, and the meningioma subtype and hormone-receptor findings can tie the biology together.

Finally, expect Daubert-style challenges to the plaintiffs’ scientific experts, an attempt to keep the causation testimony out of court entirely. This is one reason the choice of firm matters so much — the litigation is won or lost partly on the quality of the experts a firm can field and fund.

For an individual claimant, the takeaway is simple. You cannot control the science fight, but you can control your file. Longer documented use, a precise diagnosis, clean surgical and pathology records, and an honest, complete medical history are what let your lawyer slot you into a higher injury tier and blunt the alternative-cause attack.

Bottom line

Three things carry the whole effort. Confirm you can link duration of use to the diagnosis on paper. Get a free consultation with a product-liability or mass-tort attorney to check eligibility and your filing deadline. And ignore the settlement numbers floating around — build the record on the facts that actually move an injury tier: surgery, permanent deficits, and lost income. Follow that order and the intimidating MDL machinery breaks down into steps one person can manage.

---

This article is general information, not legal advice. Eligibility, filing deadlines, and the likelihood of recovery depend on the specific facts of each case, so any decision to pursue a claim should be made only after an individual consultation with a qualified attorney licensed in your jurisdiction. The litigation status and regulatory actions described here reflect the time of writing and may change.